Promising Top-Line Results for RSV Vaccine in Immunocompromised Adults

Pfizer’s ABRYSVO vaccine was safe and generated a strong immune response against respiratory syncytial virus (RSV) in immunocompromised adults aged 18 years or older, according to top-line clinical trial results announced in August. Last year, the US Food and Drug Administration approved ABRYVSO for use in people aged 60 years or older, but there is no RSV vaccine available for younger adults, even though immunocompromised individuals of any age have an increased risk of RSV complications, Pfizer noted in its news release.